Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | MTAP | Q13126 | 7/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | PNP | P00491 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13847060 | 0.85 | ADORA2A (0.48) | ADORA2AADORA3PNP | |
| SCHEMBL3986874 | 0.85 | ADORA2A (0.48) | ADORA2AADORA3PNP | |
| SCHEMBL13843297 | 0.85 | ADORA2A (0.48) | ADORA2AADORA3PNP | |
| SCHEMBL13847233 | 0.79 | MTAP (0.50) | MTAPPNP | |
| SCHEMBL13847197 | 0.78 | ADORA2A (0.35) | ADORA2APRMT5WDR77ADORA3 | |
| SCHEMBL13846986 | 0.74 | PNP (0.34) | PNP | |
| SCHEMBL13847172 | 0.73 | ADORA2A (0.35) | ADORA2APRMT5WDR77ADORA3 | |
| SCHEMBL13847181 | 0.68 | ADORA2A (0.34) | ADORA2AADORA3 | |
| SCHEMBL13847179 | 0.68 | MTAP (0.52) | MTAPPNP | |
| SCHEMBL866604 | 0.67 | PI4KA (0.50) | ADORA2AADORA3PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534767-B2 | C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase | MERCK & CO., INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20080021047-A1 | C-Purine Nucleoside Analogs As Inhibitors Of Rna-Dependent Rna Viral Polymerase | MERCK SHARP & DOHME LLC | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021047-A1 | C-Purine Nucleoside Analogs As Inhibitors Of Rna-Dependent Rna Viral Polymerase | NSUN2, PNP, RNGTT | ADORA2A 106/4885MTAP 9/4885PRMT5 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.